These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 9438158

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. E-rosette formation in Graves' ophthalmopathy.
    Sergott RC, Felberg NT, Savino PJ, Blizzard JJ, Schatz NJ.
    Invest Ophthalmol Vis Sci; 1979 Dec; 18(12):1245-51. PubMed ID: 92464
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
    De Bellis A, Sansone D, Coronella C, Conte M, Iorio S, Perrino S, Battaglia M, Bellastella G, Wall JR, Bellastella A, Bizzarro A.
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Pathogenesis and treatment of the ophthalmopathy associated with Graves' disease.
    Velkeniers B, Salu P.
    Bull Soc Belge Ophtalmol; 1992 Jan; 245():9-14. PubMed ID: 1344754
    [Abstract] [Full Text] [Related]

  • 28. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease.
    Sato A, Takemura Y, Yamada T, Ohtsuka H, Sakai H, Miyahara Y, Aizawa T, Terao A, Onuma S, Junen K, Kanamori A, Nakamura Y, Tejima E, Ito Y, Kamijo K.
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3602-5. PubMed ID: 10523002
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts.
    Grubeck-Loebenstein B, Trieb K, Sztankay A, Holter W, Anderl H, Wick G.
    J Clin Invest; 1994 Jun; 93(6):2738-43. PubMed ID: 8201012
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Determination of urinary mucopolysaccharides in Graves' disease.
    Ursu H, Dumitrescu C, Bartoc R, Dumitriu L.
    Endocrinologie; 1984 Jun; 22(4):277-82. PubMed ID: 6240765
    [Abstract] [Full Text] [Related]

  • 37. [Immunologic analysis of Graves' ophthalmopathy and ophthalmic Graves' disease].
    Liao ZQ.
    Zhonghua Yan Ke Za Zhi; 1990 May; 26(3):162-4. PubMed ID: 2144488
    [Abstract] [Full Text] [Related]

  • 38. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
    De Bellis A, Di Martino S, Fiordelisi F, Muccitelli VI, Sinisi AA, Abbate GF, Gargano D, Bellastella A, Bizzarro A.
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
    [Abstract] [Full Text] [Related]

  • 39. Immunohistochemical staining of normal and Graves' extraocular muscle.
    Tallstedt L, Norberg R.
    Invest Ophthalmol Vis Sci; 1988 Feb; 29(2):175-84. PubMed ID: 2448263
    [Abstract] [Full Text] [Related]

  • 40. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves' ophthalmopathy.
    Legler UF.
    Horm Metab Res; 1987 Apr; 19(4):168-70. PubMed ID: 3583222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.